Serious adverse events · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Intervention not reported
Serious adverse events · children with acute asthma
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for the development of type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for the development of type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with multifocal motor neuropathy
1 finding from 1 review
Serious adverse events · Children and adults with blood smear positive P. vivax malaria1
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious local adverse events (low risk of bias) inactivated HAV… (high certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious systemic adverse events (low risk of bias) inactivated… (high certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found